Will Mounjaro’s list price drop in 2026?
Mounjaro (tirzepatide) is still covered by active manufacturer pricing and market competition dynamics. Based on the information provided here, there is not enough data to say whether Eli Lilly will reduce Mounjaro’s price specifically in 2026.
Drug pricing changes for the same drug can come from several different places (not just the manufacturer lowering “the price”):
- Contracting and rebates that change what insurers/pharmacies pay
- Changes in pharmacy benefit design (copays/coinsurance)
- Broader competition (including other GLP-1/GIP products), which can pressure pricing even if list price stays similar
- Short-term supply fluctuations affecting how much discounts or promotions are visible at the pharmacy counter
Will insurance copays for Mounjaro fall in 2026 even if the list price doesn’t?
Often, the more noticeable change for patients is not the drug’s list price but the out-of-pocket price under insurance. Copays in 2026 can drop if plans:
- Update formularies to place Mounjaro on a lower tier
- Negotiate stronger rebates that reduce patient cost-sharing
- Expand coverage rules or reduce prior authorization barriers
At the same time, copays can also rise if:
- Plans move it to a higher tier
- Insurers tighten criteria for coverage
- Member cost-sharing increases
Is a price drop in 2026 tied to patent or exclusivity ending?
A common reason to expect lower prices is when exclusivity ends and cheaper competitors enter. Whether that happens in 2026 depends on the specific patent/exclusivity status for tirzepatide (and the manufacturer’s strategy), which isn’t included in the provided information.
If you want, tell me your country (US, UK, Canada, etc.) and whether you mean “list price” or “what I pay at the pharmacy,” and I can tailor the answer to the relevant pricing and exclusivity landscape.
How to check whether price reductions are likely for your situation
If you’re trying to predict what you’ll pay in 2026, look for:
- Your insurer’s formulary updates (usually published before the new plan year)
- Your pharmacy benefit manager (PBM) notices about tier placement or cost-sharing changes
- Any manufacturer savings program changes (these can change net cost even when list price doesn’t)
Where to verify drug pricing and exclusivity signals
For up-to-date patent and exclusivity details that can drive competition timing, DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/
Sources:
1. https://www.drugpatentwatch.com/